Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial

International Journal of Cardiology

Volumn 176, Issue 1, 2014, Pages 55-61

  Roth, Eli M ^a   Taskinen, Marja Riitta ^b   Ginsberg, Henry N ^c   Kastelein, John J P ^d   Colhoun, Helen M ^e   Robinson, Jennifer G ^f   Merlet, Laurence ^g   Pordy, Robert ^h   Baccara Dinet, Marie T ^g  

^a Sterling Research Group   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f UNIVERSITY OF IOWA   (United States)

^g SANOFI   (France)

^h REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Alirocumab; Cholesterol lowering drugs; Hypercholesterolemia; LDL C; Monoclonal antibodies; PCSK9

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALIROCUMAB; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; EZETIMIBE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ABDOMINAL CRAMP; ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOINJECTOR; BACKACHE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GLENOID EROSION; GLUCOSE BLOOD LEVEL; GOUT; HEADACHE; HEART ATRIUM FIBRILLATION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; INFLUENZA; INJECTION SITE REACTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUSCLE DISEASE; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SHOULDER ARTHROPLASTY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY FREQUENCY; URINARY TRACT INFECTION; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED;

AGED; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84906323762     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.06.049     Document Type: Article

References (23)

1. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
2. E.M. Roth, J.M. McKenney, C. Hanotin, G. Asset, and E.A. Stein Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
3. E.A. Stein, D. Gipe, and J. Bergeron et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
4. E.A. Stein, S. Mellis, and G.D. Yancopoulos et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 2012 1108 1118
5. R.M. Conroy, K. Pyorala, and A.P. Fitzgerald et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 2003 987 1003 (Pubitemid 36712275)
6. National Institute for Health and Clinical Excellence NICE technology appraisal guidance TA132. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia Available at: http://publications.nice.org.uk/ezetimibe-for-the-treatment-of-primary- heterozygous-familial-and-non-familial-ta132 2007 [Accessed March 28, 2014]
7. R. Pordy, G. Lecrops, L. Bessac, W.G. Sasiela, and H. Ginsberg Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9: therapeutic dosing in Phase 3 studies J Clin Lipidol 7 2013 279 [abstract]
8. J. Perk, B.G. De, and H. Gohlke et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Atherosclerosis 223 2012 1 68
9. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423
10. S.J. Nicholls, G. Brandrup-Wognsen, M. Palmer, and P.J. Barter Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER) Am J Cardiol 105 2010 69 76
11. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2013 2889 2934
12. M.J. Koren, R. Scott, and J.B. Kim et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study Lancet 380 2012 1995 2006
13. C.M. Ballantyne, J. Houri, and A. Notarbartolo et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial Circulation 107 2003 2409 2415 (Pubitemid 36605221)
14. R.H. Knopp, H. Gitter, and T. Truitt et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia Eur Heart J 24 2003 729 741 (Pubitemid 36458985)
15. S. Genuth, K.G. Alberti, and P. Bennett et al. Follow-up report on the diagnosis of diabetes mellitus Diabetes Care 26 2003 3160 3167
16. M. Mbikay, F. Sirois, and J. Mayne et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities FEBS Lett 584 2010 701 706
17. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
18. A.J. Hooper, A.D. Marais, D.M. Tanyanyiwa, and J.R. Burnett The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population Atherosclerosis 193 2007 445 448 (Pubitemid 47058112)
19. Z. Zhao, Y. Tuakli-Wosornu, and T.A. Lagace et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote Am J Hum Genet 79 2006 514 523 (Pubitemid 44384260)
20. Z. Awan, E.E. Delvin, and E. Levy et al. Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype Can J Cardiol 29 2013 927 933
21. D.J. Blom, T. Hala, and M. Bolognese et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819
22. M.J. Koren, R.P. Giugliano, and F.J. Raal et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial Circulation 129 2014 234 243
23. M.J. Koren, P. Lundqvist, and M. Bolognese et al. Anti-PCSK9 monotherapy for hypercholesterolemia - the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 17 2014 2531 2540